Eagle Pharmaceuticals Reports First Quarter 2023 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 33c; Offers FY23 EPS Guidance
May 9, 2023 6:52 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.26, $0.33 better than the analyst estimate of $0.93. Revenue for the quarter came in at $66.3 million versus the consensus estimate of $63.29 million.
GUIDANCE:
Eagle Pharmaceuticals sees FY2023 EPS of $4.20-$4.53, versus the consensus of... More
